Clinical Efficacy of Capecitabine and Docetaxel Efficacy in Advanced Triple-Negative Breast Cancer Along with Ultrasound-Mediated Drug Delivery.

In 30 seconds

This randomized controlled trial compared two regimens in 80 patients with advanced triple-negative breast cancer: capecitabine and docetaxel with ultrasound-mediated drug delivery, versus cisplatin and docetaxel. After two treatment cycles, the ultrasound-supported regimen was associated with higher response and disease control rates, better preservation of immunoglobulin levels and FACT-B quality-of-life scores, and larger reductions in CA125 and CA153. Adverse events were less frequent in the ultrasound group, but the between-group difference was not statistically significant. The abstract does not report numerical response rates or effect sizes.

Key findings

• Response and disease control rates were higher with ultrasound-supported capecitabine and docetaxel than with cisplatin and docetaxel (p < 0.05).
• After two cycles, IgG, IgM, and IgA decreased in the control group but were maintained at higher levels in the ultrasound group (p < 0.05).
• FACT-B scores declined in both groups, with a smaller reduction in the ultrasound group (p < 0.05).
• Adverse events were less frequent with ultrasound-supported treatment, but the difference was not statistically significant (p > 0.05).

Why it matters

The findings suggest that ultrasound-mediated delivery paired with capecitabine and docetaxel may improve measured tumour response while better preserving immune markers and quality of life than the comparator regimen. These outcomes are relevant when evaluating treatment strategies for advanced TNBC, although the abstract provides no numerical effect estimates to judge the magnitude of benefit.

What to keep in mind

The abstract reports results from 80 patients treated at one institution and does not provide numerical response rates or effect sizes, limiting assessment of the magnitude and precision of the reported differences.